Addex Therapeutics (ADXN) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ADXN Stock Forecast

Addex Therapeutics stock forecast is as follows: an average price target of $30.00 (represents a 281.68% upside from ADXN’s last price of $7.86) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

ADXN Price Target

The average price target for Addex Therapeutics (ADXN) is $30.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $30.00. This represents a potential 281.68% upside from ADXN's last price of $7.86.

ADXN Analyst Ratings

Buy

According to 1 Wall Street analysts, Addex Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ADXN stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Addex Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 28, 2024	Raghuram Selvaraju	H.C. Wainwright	$30.00	$10.52	185.11%	281.68%

The latest Addex Therapeutics stock forecast, released on Aug 28, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $30.00, which represents a 185.11% increase from the stock price at the time of the forecast ($10.52), and a 281.68% increase from ADXN last price ($7.86).

Addex Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$30.00
Last Closing Price	$7.86	$7.86	$7.86
Upside/Downside	-100.00%	-100.00%	281.68%

In the current month, the average price target of Addex Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Addex Therapeutics's last price of $7.86. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 28, 2024	H.C. Wainwright	Buy	Buy	Hold

Addex Therapeutics's last stock rating was published by H.C. Wainwright on Aug 28, 2024. The company gave ADXN a "Buy" rating, the same as its previous rate.

Addex Therapeutics Financial Forecast

Addex Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
Revenue	-	-	-	-	-	-	-	-	-	-	-	$500.89K	$592.43K	$409.42K	$183.35K	$237.24K	$397.49K	$682.00K	$992.60K	$844.22K
Avg Forecast	$201.02K	$201.02K	$201.02K	$201.02K	$201.02K	$99.44K	$213.50K	$698.73K	$660.97K	$607.13K	$277.19K	$283.21K	$238.34K	$228.63K	$508.13K	$467.92K	$470.75K	$385.45K	$238.08K	$721.37K
High Forecast	$201.02K	$201.02K	$201.02K	$201.02K	$201.02K	$99.44K	$218.59K	$698.73K	$660.97K	$607.26K	$277.19K	$283.21K	$238.34K	$228.63K	$508.13K	$467.92K	$470.75K	$385.45K	$238.08K	$721.37K
Low Forecast	$201.02K	$201.02K	$201.02K	$201.02K	$201.02K	$99.44K	$208.41K	$698.73K	$660.97K	$606.99K	$277.19K	$283.21K	$238.34K	$228.63K	$508.13K	$467.92K	$470.75K	$385.45K	$238.08K	$721.37K
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	-	-	1.77%	2.49%	1.79%	0.36%	0.51%	0.84%	1.77%	4.17%	1.17%

Addex Therapeutics's average Quarter revenue forecast for Jun 23 based on 1 analysts is $277.19K, with a low forecast of $277.19K, and a high forecast of $277.19K. ADXN's average Quarter revenue forecast represents a -44.66% decrease compared to the company's last Quarter revenue of $500.89K (Mar 23).

Addex Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	-	-	$-2.30M	$-3.40M	$-4.09M	$-7.01M	$-5.68M	$-4.33M	$-3.50M	$-4.58M	$-2.53M
Avg Forecast	$-201.02K	$-201.02K	$-201.02K	$-201.02K	$-201.02K	$-99.44K	$-213.50K	$-698.73K	$-660.97K	$-607.13K	$-277.19K	$-283.21K	$-238.34K	$-228.63K	$-508.13K	$-3.50M	$-470.75K	$-385.45K	$-3.44M	$-721.37K
High Forecast	$-201.02K	$-201.02K	$-201.02K	$-201.02K	$-201.02K	$-99.44K	$-208.41K	$-698.73K	$-660.97K	$-606.99K	$-277.19K	$-283.21K	$-238.34K	$-228.63K	$-508.13K	$-2.80M	$-470.75K	$-385.45K	$-2.75M	$-721.37K
Low Forecast	$-201.02K	$-201.02K	$-201.02K	$-201.02K	$-201.02K	$-99.44K	$-218.59K	$-698.73K	$-660.97K	$-607.26K	$-277.19K	$-283.21K	$-238.34K	$-228.63K	$-508.13K	$-4.20M	$-470.75K	$-385.45K	$-4.13M	$-721.37K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	8.12%	14.25%	17.87%	13.79%	1.62%	9.20%	9.08%	1.33%	3.51%

undefined analysts predict ADXN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Addex Therapeutics's previous annual EBITDA (undefined) of $NaN.

Addex Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	-	-	$-2.43M	$-3.82M	$-4.05M	$-7.35M	$-5.88M	$-4.43M	$-3.60M	$-4.69M	$-2.64M
Avg Forecast	$-117.99M	$-117.99M	$-117.99M	$-352.91M	$-117.64M	$-116.38M	$-124.94M	$-38.94M	$-55.26M	$-59.22M	$-72.10M	$-92.08M	$-92.99M	$-178.40M	$-252.66M	$-3.59M	$-1.16B	$-1.55B	$-3.53M	$-1.21B
High Forecast	$-117.99M	$-117.99M	$-117.99M	$-352.91M	$-117.64M	$-116.38M	$-124.94M	$-38.94M	$-55.26M	$-59.22M	$-72.10M	$-92.08M	$-92.99M	$-178.40M	$-252.66M	$-2.87M	$-1.16B	$-1.55B	$-2.82M	$-1.21B
Low Forecast	$-117.99M	$-117.99M	$-117.99M	$-352.91M	$-117.64M	$-116.38M	$-124.94M	$-38.94M	$-55.26M	$-59.22M	$-72.10M	$-92.08M	$-92.99M	$-178.40M	$-252.66M	$-4.31M	$-1.16B	$-1.55B	$-4.23M	$-1.21B
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.03%	0.04%	0.02%	0.03%	1.64%	0.00%	0.00%	1.33%	0.00%

Addex Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ADXN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Addex Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	-	-	$1.80M	$-240.68K	$2.39M	$1.53M	$2.24M	$497.58K	$1.47M	$1.85M	$1.32M
Avg Forecast	$576.06K	$576.06K	$576.06K	$576.06K	$576.06K	$284.96K	$611.83K	$2.00M	$1.89M	$1.74M	$794.35K	$811.61K	$683.02K	$655.20K	$1.46M	$1.34M	$1.35M	$1.10M	$682.27K	$2.07M
High Forecast	$576.06K	$576.06K	$576.06K	$576.06K	$576.06K	$284.96K	$626.42K	$2.00M	$1.89M	$1.74M	$794.35K	$811.61K	$683.02K	$655.20K	$1.46M	$1.34M	$1.35M	$1.10M	$682.27K	$2.07M
Low Forecast	$576.06K	$576.06K	$576.06K	$576.06K	$576.06K	$284.96K	$597.24K	$2.00M	$1.89M	$1.74M	$794.35K	$811.61K	$683.02K	$655.20K	$1.46M	$1.34M	$1.35M	$1.10M	$682.27K	$2.07M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	2.22%	-0.35%	3.65%	1.05%	1.67%	0.37%	1.33%	2.71%	0.64%

Addex Therapeutics's average Quarter SG&A projection for Jun 23 is $794.35K, based on 1 Wall Street analysts, with a range of $794.35K to $794.35K. The forecast indicates a -55.91% fall compared to ADXN last annual SG&A of $1.80M (Mar 23).

Addex Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	-	-	$-0.24	$-0.51	$-0.51	$-1.18	$-0.93	$-0.78	$-0.66	$-0.84	$-0.48
Avg Forecast	$-1.21	$-1.21	$-1.21	$-3.62	$-1.21	$-1.19	$-1.28	$-0.40	$-0.57	$-0.61	$-0.74	$-0.94	$-0.95	$-1.83	$-2.59	$-9.56	$-11.87	$-15.87	$-14.53	$-12.37
High Forecast	$-1.21	$-1.21	$-1.21	$-3.62	$-1.21	$-1.19	$-1.28	$-0.40	$-0.57	$-0.61	$-0.74	$-0.94	$-0.95	$-1.83	$-2.59	$-9.56	$-11.87	$-15.87	$-14.53	$-12.37
Low Forecast	$-1.21	$-1.21	$-1.21	$-3.62	$-1.21	$-1.19	$-1.28	$-0.40	$-0.57	$-0.61	$-0.74	$-0.94	$-0.95	$-1.83	$-2.59	$-9.56	$-11.87	$-15.87	$-14.53	$-12.37
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.25%	0.53%	0.28%	0.46%	0.10%	0.07%	0.04%	0.06%	0.04%

According to undefined Wall Street analysts, Addex Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ADXN previous annual EPS of $NaN (undefined).

Addex Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ATXI	Avenue Therapeutics	$1.66	$12.00	622.89%	Buy
IPHA	Innate Pharma	$2.15	$10.00	365.12%	Buy
LRMR	Larimar Therapeutics	$4.32	$17.00	293.52%	Buy
ADXN	Addex Therapeutics	$7.80	$30.00	284.62%	Buy
ACHL	Achilles Therapeutics	$0.97	$2.00	106.19%	Buy
KRON	Kronos Bio	$0.96	$1.00	4.17%	Buy

ADXN Forecast FAQ

Is Addex Therapeutics a good buy?

Yes, according to 1 Wall Street analysts, Addex Therapeutics (ADXN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of ADXN's total ratings.

What is ADXN's price target?

Addex Therapeutics (ADXN) average price target is $30 with a range of $30 to $30, implying a 281.68% from its last price of $7.86. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Addex Therapeutics stock go up soon?

According to Wall Street analysts' prediction for ADXN stock, the company can go up by 281.68% (from the last price of $7.86 to the average price target of $30), up by 281.68% based on the highest stock price target, and up by 281.68% based on the lowest stock price target.

Can Addex Therapeutics stock reach $12?

ADXN's average twelve months analyst stock price target of $30 supports the claim that Addex Therapeutics can reach $12 in the near future.

What are Addex Therapeutics's analysts' financial forecasts?

Addex Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $1.21M (high $1.22M, low $1.21M), average EBITDA is $-1.213M (high $-1.208M, low $-1.218M), average net income is $-398M (high $-398M, low $-398M), average SG&A $3.48M (high $3.49M, low $3.46M), and average EPS is $-4.08 (high $-4.08, low $-4.08). ADXN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $804.08K (high $804.08K, low $804.08K), average EBITDA is $-804K (high $-804K, low $-804K), average net income is $-707M (high $-707M, low $-707M), average SG&A $2.3M (high $2.3M, low $2.3M), and average EPS is $-7.247 (high $-7.247, low $-7.247).

Did the ADXN's actual financial results beat the analysts' financial forecasts?

Based on Addex Therapeutics's last annual report (Dec 2022), the company's revenue was $1.42M, which missed the average analysts forecast of $1.44M by -1.43%. Apple's EBITDA was $-20.168M, beating the average prediction of $-4.474M by 350.81%. The company's net income was $-21.069M, missing the average estimation of $-528M by -96.01%. Apple's SG&A was $7.3M, beating the average forecast of $4.14M by 76.52%. Lastly, the company's EPS was $-2.8, missing the average prediction of $-14.93 by -81.25%. In terms of the last quarterly report (Mar 2023), Addex Therapeutics's revenue was $500.89K, beating the average analysts' forecast of $283.22K by 76.86%. The company's EBITDA was $-2.3M, beating the average prediction of $-283K by 712.07%. Addex Therapeutics's net income was $-2.433M, missing the average estimation of $-92.079M by -97.36%. The company's SG&A was $1.8M, beating the average forecast of $811.61K by 121.96%. Lastly, the company's EPS was $-0.24, missing the average prediction of $-0.944 by -74.58%